ANI Pharmaceuticals Inc (ANIP)
55.86
+0.76
(+1.38%)
USD |
NASDAQ |
Nov 21, 16:00
55.82
-0.04
(-0.07%)
After-Hours: 20:00
ANI Pharmaceuticals Enterprise Value: 1.671B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.671B |
| November 20, 2024 | 1.655B |
| November 19, 2024 | 1.667B |
| November 18, 2024 | 1.658B |
| November 15, 2024 | 1.686B |
| November 14, 2024 | 1.735B |
| November 13, 2024 | 1.754B |
| November 12, 2024 | 1.779B |
| November 11, 2024 | 1.795B |
| November 08, 2024 | 1.788B |
| November 07, 2024 | 1.724B |
| November 06, 2024 | 1.724B |
| November 05, 2024 | 1.701B |
| November 04, 2024 | 1.674B |
| November 01, 2024 | 1.720B |
| October 31, 2024 | 1.703B |
| October 30, 2024 | 1.730B |
| October 29, 2024 | 1.740B |
| October 28, 2024 | 1.718B |
| October 25, 2024 | 1.726B |
| October 24, 2024 | 1.746B |
| October 23, 2024 | 1.741B |
| October 22, 2024 | 1.763B |
| October 21, 2024 | 1.746B |
| October 18, 2024 | 1.768B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.764B |
| October 16, 2024 | 1.754B |
| October 15, 2024 | 1.732B |
| October 14, 2024 | 1.730B |
| October 11, 2024 | 1.701B |
| October 10, 2024 | 1.658B |
| October 09, 2024 | 1.692B |
| October 08, 2024 | 1.693B |
| October 07, 2024 | 1.673B |
| October 04, 2024 | 1.715B |
| October 03, 2024 | 1.693B |
| October 02, 2024 | 1.708B |
| October 01, 2024 | 1.750B |
| September 30, 2024 | 1.754B |
| September 27, 2024 | 1.299B |
| September 26, 2024 | 1.289B |
| September 25, 2024 | 1.268B |
| September 24, 2024 | 1.294B |
| September 23, 2024 | 1.327B |
| September 20, 2024 | 1.318B |
| September 19, 2024 | 1.333B |
| September 18, 2024 | 1.347B |
| September 17, 2024 | 1.326B |
| September 16, 2024 | 1.245B |
| September 13, 2024 | 1.294B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
462.56M
Minimum
Nov 06 2020
1.795B
Maximum
Nov 11 2024
925.76M
Average
871.91M
Median
Aug 23 2022
Enterprise Value Benchmarks
| Windtree Therapeutics Inc | 0.5065M |
| Allogene Therapeutics Inc | 150.84M |
| AIM ImmunoTech Inc | 9.017M |
| Protalix BioTherapeutics Inc | 94.82M |
| Armata Pharmaceuticals Inc | 166.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.17M |
| Revenue (Quarterly) | 148.33M |
| Total Expenses (Quarterly) | 168.03M |
| EPS Diluted (Quarterly) | -1.27 |
| Gross Profit Margin (Quarterly) | 57.48% |
| Profit Margin (Quarterly) | -16.29% |
| Earnings Yield | -1.02% |
| Operating Earnings Yield | 0.89% |
| Normalized Earnings Yield | -1.088 |